Today, value-based healthcare is growing, and small details can lead to significant value for patients, caregivers, and enterprises. A truly hybrid system, Biograph™ mCT supports high levels of productivity, and has the flexibility to accommodate all patients1 and procedures—enhancing your ability to offer better care. Biograph mCT’s digital detectors leverage small 4 x 4-mm LSO crystal elements to deliver high-resolution images. In addition, true time of flight (TOF) provides improved contrast definition, allowing for the delineation of small lesions and precise anatomical detail. Biograph mCT’s 78-cm bore size combined with AIDAN, our intelligent imaging platform for PET/CT, let you deliver an enhanced patient and user experience for faster and more reproducible workflows—giving you more time to focus on better care for your patients.
Biograph mCT
Clearly going beyond
Features & Benefits
Innovative technology for better care
Accelerate your potential with technologies that go beyond the standard level of imaging. Serve more patients and grow your business with enhanced technological and clinical efficiencies that empower you to access more steps across the entire patient journey. With intelligent imaging and the ability to accommodate all patients,1 Biograph mCT moves the patient and user experience to a new level of care.
Technology that takes you further
The high 78-mm3 volumetric resolution2 and 4 x 4-mm LSO crystal elements of the Biograph mCT bring enhanced detectability with accurate and reproducible quantification. True TOF capabilities and innovative technologies such as FlowMotion™ help you lead the way in technological and medical advancement. Powerful CT solutions ranging from 40 to 128 slices with low-dose technologies give you the flexibility to go beyond standard care.
Clinical solutions for beyond today
Biograph mCT supports the clinical development of PET/CT imaging in oncology, cardiology, and neurology. Delivering customizable solutions for diagnostic, theranostic, radiation therapy planning, and research imaging, Biograph mCT lets you redefine clinical decision-making.
A next-level experience for all
The large bore and high weight capacity of Biograph mCT combined with intelligent imaging capabilities let you deliver a next-level patient and user experience. Accommodate all patients1 and procedures for both PET and CT with optimized patient positioning and an easy-to-use interface. AI-powered features enable automation for faster, more reproducible workflows—giving you more time with your patients.
AIDAN Platform
Our intelligent imaging platform for Biograph PET/CT scanners that supports the demanding processing power of AI-based solutions.
Click plus (+) to find out our features
Exclusive bed design and wide bore
Digital LSO-based detectorsCT capability
iMAR
SAFIRE
Whole-body dynamic imaging
True time of flight
TrueV extended PET field of view
QualityGuard™
HD•PET
FlowMotion™ AI
FAST PET Workflow AI
Multiparametric PET Suite AI
OncoFreeze™ / OncoFreeze AI
Our customers say...
“The AIDAN platform is a nice foundation to highlight and leverage the strengths of the AI implementations.”3
Director, Clinical Research
Knoxville, Tennessee (USA)
“With FlowMotion™ AI, we can guarantee that every patient who comes in is going to get very consistent planning.”3
Director, Clinical Research
Knoxville, Tennessee (USA)
“With OncoFreeze™ AI, we can now offer motion correction to all of our patients, regardless of whether they're coming in with a specific type of disease or not.”3
Director, Clinical Research
Knoxville, Tennessee (USA)
Clinical Use
Case 1
01Case 2
01Case 3
01Case 4
01Case 5
01Case 5
PET/CT helps delineation of radiotherapy target volume with implication for dose escalation in rectal cancer
- 18F FDG PET/CT delineates large, hypermetabolic rectal carcinoma with small solitary hypermetabolic presacral lymph node
- The radiation therapy plan was altered in order to include the solitary presacral node in the gross tumor volume (GTV)
- Total dose prescribed was 54 Gy to GTV at 1.8 Gy per fraction with dose escalation to the area with highest tracer uptake
Biograph mCT PET/CT
PET
Image reconstruction: 200 x 200 matrix, PSF+TOF 3i21s
Scan time: 7 bed positions/3 min per bed
Total scan time: 21 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
10 mCi (370 MBq)
CT
Scan parameters 120 kV/57 ref mAs
Case 1
PET resting perfusion and viability study in a patient with a BMI above 40
- Resting perfusion shows large anteroseptal defect, which shows normal FDG uptake, suggesting it is severely ischemic but viable myocardium
- High contrast of left ventricular myocardium achieved on Biograph mCT leads to sharp definition of ventricular walls and ischemic segments in an obese patient
Biograph mCT PET/CT
PET
Scan acquisition: 200 x 200 matrix, OSEM3D 4i24s
Scan time: 6 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection[a]
20 mCi (740 MBq)
CT
Scan parameters: 120 kV / 81 ref mAs
Case 2
Excellent delineation of cerebral cortex and basal ganglia with ultraHD•PET
- ultra•HD PET yeilds excellent white/gray matter contrast and anatomical detail in brain imaging even at lower injected doses
- TrueV allows faster acquistion and higher count statistics further improving target to background contrast
Biograph mCT PET/CT
PET
Scan acquisition: 400 x 400 matrix, PSF+TOF 5i21s
Scan time: 15 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
6.0 mCi (221 MBq)
CT
Scan parameters: 120 kV / 274 ref mAs
Case 3
Malignant melanoma with brain and lung metastasis
Integration of respiratory gating in whole-body protocols
Variable acquisition speed with slower scanning in the head and neck and respiratory gating in the thorax made possible by FlowMotion™ acquisition enable Hi-Rez reconstruction of brain and HD•Chest for thorax for sharp delineation of brain and lung metastases in a patient with advanced melanorma.
Biograph mCT Flow™ PET/CT
PET
Scan acquisition: 200 x 200 matrix, PSF+TOF 3i21s
Scan time: 1.2 mm/s head 0.4 mm/s thorax (gated) 2.1 mm/s abdomen to toes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
9 mCi (333 MBq)
CT
Scan parameters: 120 kV / 100 ref mAs
Case 4
Large bore and high-weight capacity enabled imaging of markedly obese pediatric lymphoma patient
- 78-cm bore gantry opening (8 cm above the industry standard) accommodates larger body habitus
- Gantry table accommodates weights up to 500 lb ( 227 kg), allowing more of the varied patient population to be imaged
- Non-deflecting table allows good image quality throughout the scan as it stays consistent through both the PET and CT fields-of-view ensuring accurate registration
Biograph mCT PET/CT
PET
Scan acquisition: 200 x 200 matrix, PSF 3i24s
Scan time: 3 minutes per bed
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
15.6 mCi (577 MBq)
CT
Scan parameters: 120 kV / 70 ref mAs
Case 5
PET/CT helps delineation of radiotherapy target volume with implication for dose escalation in rectal cancer
- 18F FDG PET/CT delineates large, hypermetabolic rectal carcinoma with small solitary hypermetabolic presacral lymph node
- The radiation therapy plan was altered in order to include the solitary presacral node in the gross tumor volume (GTV)
- Total dose prescribed was 54 Gy to GTV at 1.8 Gy per fraction with dose escalation to the area with highest tracer uptake
Biograph mCT PET/CT
PET
Image reconstruction: 200 x 200 matrix, PSF+TOF 3i21s
Scan time: 7 bed positions/3 min per bed
Total scan time: 21 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
10 mCi (370 MBq)
CT
Scan parameters 120 kV/57 ref mAs
Case 1
PET resting perfusion and viability study in a patient with a BMI above 40
- Resting perfusion shows large anteroseptal defect, which shows normal FDG uptake, suggesting it is severely ischemic but viable myocardium
- High contrast of left ventricular myocardium achieved on Biograph mCT leads to sharp definition of ventricular walls and ischemic segments in an obese patient
Biograph mCT PET/CT
PET
Scan acquisition: 200 x 200 matrix, OSEM3D 4i24s
Scan time: 6 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection[a]
20 mCi (740 MBq)
CT
Scan parameters: 120 kV / 81 ref mAs
Case 2
Excellent delineation of cerebral cortex and basal ganglia with ultraHD•PET
- ultra•HD PET yeilds excellent white/gray matter contrast and anatomical detail in brain imaging even at lower injected doses
- TrueV allows faster acquistion and higher count statistics further improving target to background contrast
Biograph mCT PET/CT
PET
Scan acquisition: 400 x 400 matrix, PSF+TOF 5i21s
Scan time: 15 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
6.0 mCi (221 MBq)
CT
Scan parameters: 120 kV / 274 ref mAs
Case 3
Malignant melanoma with brain and lung metastasis
Integration of respiratory gating in whole-body protocols
Variable acquisition speed with slower scanning in the head and neck and respiratory gating in the thorax made possible by FlowMotion™ acquisition enable Hi-Rez reconstruction of brain and HD•Chest for thorax for sharp delineation of brain and lung metastases in a patient with advanced melanorma.
Biograph mCT Flow™ PET/CT
PET
Scan acquisition: 200 x 200 matrix, PSF+TOF 3i21s
Scan time: 1.2 mm/s head 0.4 mm/s thorax (gated) 2.1 mm/s abdomen to toes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
9 mCi (333 MBq)
CT
Scan parameters: 120 kV / 100 ref mAs
Case 4
Large bore and high-weight capacity enabled imaging of markedly obese pediatric lymphoma patient
- 78-cm bore gantry opening (8 cm above the industry standard) accommodates larger body habitus
- Gantry table accommodates weights up to 500 lb ( 227 kg), allowing more of the varied patient population to be imaged
- Non-deflecting table allows good image quality throughout the scan as it stays consistent through both the PET and CT fields-of-view ensuring accurate registration
Biograph mCT PET/CT
PET
Scan acquisition: 200 x 200 matrix, PSF 3i24s
Scan time: 3 minutes per bed
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
15.6 mCi (577 MBq)
CT
Scan parameters: 120 kV / 70 ref mAs
Case 5
PET/CT helps delineation of radiotherapy target volume with implication for dose escalation in rectal cancer
- 18F FDG PET/CT delineates large, hypermetabolic rectal carcinoma with small solitary hypermetabolic presacral lymph node
- The radiation therapy plan was altered in order to include the solitary presacral node in the gross tumor volume (GTV)
- Total dose prescribed was 54 Gy to GTV at 1.8 Gy per fraction with dose escalation to the area with highest tracer uptake
Biograph mCT PET/CT
PET
Image reconstruction: 200 x 200 matrix, PSF+TOF 3i21s
Scan time: 7 bed positions/3 min per bed
Total scan time: 21 minutes
Injected dose: Fludeoxyglucose F 18 (18F FDG) Injection
10 mCi (370 MBq)
CT
Scan parameters 120 kV/57 ref mAs
[a] Please see Indications and Important Safety Information for Fludeoxyglucose F 18 (18F FDG) Injection and full Prescribing Information.
Technical Specifications
Gantry |
|
Bore diameter | 78 cm |
Tunnel length | 136 cm |
Table capacity | 227 kg (500 lb) |
CT |
|
Generator power | 80 kW, 100 kW* |
Rotation times | 1.0, 0.5, 0.33, 0.30*, 0.28* s |
Tube voltages | 70, 80, 100, 120, 140 kV |
Iterative reconstruction | SAFIRE* |
Metal artifact reduction | iMAR* |
Slices | 40, 64, 128 |
PET |
|
Axial field of view | 16.4, 22.1* cm |
Crystal size | 4 x 4 x 20 mm |
True time of flight | |
Coincidence window | 4.1 ns |
Effective sensitivity | 13.2, 23.1*cps/kBq |
Effective peak NEC rate | 253 kcps ≤30 kBq/cc, 425* kcps ≤ 28 kBq/cc |
Learn more about Biograph mCT
Did this information help you?
Thank you.
Patient weight limit of 227 kg (500 lb).
The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer’s unique setting. Since there is no “typical” hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.